drugset / Trial / NCT05658016

Phase 2a Study to Evaluate Suppression of Radiotherapy-induced Mucositis by TK112690

NCT05658016 ↗

RandomizedParallel-groupTriple-blindPrevention

Summary

Patients expected to receive a continuous course of radiation as single daily fractions of 2.0 Gy treatment with a cumulative radiation dose of 70 Gy. The radiation can be 2DRT, 3DRT,IMRT etc. Prior to each radiation treatment the patients will receive a one-hour infusion of TK-90 or equivalent TK-90 placebo depending on randomization. 6 Hours after the completion of TK-90 infusion or TK-90 placebo dose, the patients will receive another identical TK-90 or TK-90 placebo treatment depending on randomization. This treatment cycle will continue for 7 weeks. The TK112690 dose will be 45 mg/kg.

Timeline

Start
2022-06-17
Primary completion
2023-09
Completion
2023-09

Drugs

EvaluationDrugModalityDoseRoute
Subject TK-112690 Small molecule 45 mg/kg Other

Indications